Authors
Latest:
Immunotherapy for NSCLC: Clinical PearlsFinal takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.
Latest:
Dr. Roy Weiner on the Importance of Diversity in Cancer ResearchRoy Weiner, MD, Associate Dean for Clinical Research and Training Associate Director of Clinical Research for Tulane Cancer Center discusses the importance of racial and ethnic diversity in cancer research.
Latest:
Addressing Unmet Needs in Medullary Thyroid CancerRozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.
Latest:
Myeloproliferative Neoplasm Management: Future Directions in CareClosing out their discussion on myeloproliferative neoplasms, key opinion leaders share excitement for future evolutions in the treatment paradigm.
Latest:
Bone Marrow Transplant for Patients With MFExpert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.
Latest:
Role of Symptom Burden in Thrombocythemia and Polycythemia VeraShared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.
Latest:
Dr. Mesa on the Rationale for the MOMENTUM Trial in MyelofibrosisRuben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.
Latest:
Dr. Niesvizky on Sequencing Therapies for Patients With Multiple MyelomaRuben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology CareUSPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.
Latest:
Dr. Yuan on Tivantinib for Hepatocellular CarcinomaDr. RuiRong Yuan, from Daiichi Sankyo, on the Efficacy of Tivantinib for Patietns With Hepatocellular Carcinoma.
Latest:
Dr. Bhatt on Finding a PD-L1 Pathway of Resistance in RCCRupal S. Bhatt, MD, PhD, discusses the potential identification of a pathway of resistance for PD-L1 in renal cell carcinoma.
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
Dr Kotecha on the FDA Approval of Optune Lua in Metastatic NSCLCRupesh Rajesh Kotecha, MD, discusses the FDA approval for Optune Lua in metastatic non–small cell lung cancer.
Latest:
Therapy Class Review: Blood ModifiersIn reviewing the therapeutic category of blood modifiers, there are 3 areas of focus
Latest:
Dr. Berman on Evolving Role of Surgery in MelanomaRussell Berman, MD, division chief of Surgical Oncology at NYU Langone Medical Center, NYU Langone School of Medicine, shares insight on the evolving role of surgery in patients with melanoma.
Latest:
Oncology Fellows: Reminding Ourselves of How Far We've ComeFor us, a group of 15 black students at Tulane University School of Medicine (TUSCOM), a visit to the Whitney Plantation in Edgard, Louisiana, was a no-brainer. The process of navigating medical school is pure hell at times, and you need inspiration wherever and whenever you can get it.
Latest:
Dr. Schilder on PARP Inhibitors in Gynecologic CancersRussell J. Schilder, MD, director, Gynecologic Medical Oncology, Thomas Jefferson University, Kimmel Cancer Center, discusses PARP inhibitors and their potential role in gynecologic cancers.
Latest:
Denosumab: A Review of Its Pharmacology and Clinical ImplicationsIt is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.
Latest:
Dr. Szmulewitz on Optimal Use of Radium-223 in mCRPCRussell Szmulewitz, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the optimal use of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Rao on Incorporating Updated NCCN Guidelines Into Treatment Selection for HER2+ Breast CancerRuta D. Rao, MD, discusses how the updated National Comprehensive Cancer Network guidelines have influenced treatment selection for patients with HER2-positive breast cancer.
Latest:
Dr. Rao on Emerging Treatments in HER2+ Metastatic Breast CancerRuta D. Rao, MD, associate professor in the Department of Medicine, Division of Hematology at Rush Medical College, as well as the director of the Coleman Foundation Comprehensive Breast Cancer Clinic and medical director of Rush University Cancer Center, discusses emerging treatments for patients with HER2-positive metastatic breast cancer.
Latest:
Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast CancerRuth O'Regan, MD, discusses considerations for sequencing strategies in advanced hormone receptor–positive breast cancer.
Latest:
Dr. O'Regan on Treatment of Breast Cancer in Premenopausal WomenRuth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses treatment for premenopausal patients with breast cancer.
Latest:
mTOR Biology and the Growing Role for mTOR Inhibitors in the Management of Breast CancerThe role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.
